Imaginab, Inc.

ImaginAb is a clinical-stage, revenue-generating global biotechnology company based in Inglewood, California, developing next-generation imaging agents and radiopharmaceutical therapy products through its proprietary minibody and cys-diabody antibody platforms. The company's lead candidate, 89Zr crefmirlimab berdoxam (CD8 ImmunoPET), is an advanced imaging agent in Phase II clinical trials that enables physicians to visualize CD8+ T-cells head-to-toe in a single whole-body scan, providing a non-invasive alternative to repeat biopsies for monitoring immune response during immunotherapy. The CD8 ImmunoPET technology has been licensed by numerous pharmaceutical and biotech companies for use in immunotherapy clinical trials, primarily in oncology. ImaginAb also collaborates with biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies, advancing a pipeline targeting oncology and autoimmune conditions including systemic sclerosis and Sjogren's syndrome.